Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Letters to the Editor

Staff  |  Issue: July 2007  |  July 1, 2007

I would have no problem injecting the knee with corticosteroids with an INR (international normalization ratio) around 3. I have injected many joints under these circumstances without any complications (just have an experienced hand perform it). Intravenous (IV) steroids can also be used.

I think that steroid use for brief periods is safe (again, from personal experience). How many chronic obstructive pulmonary disease (COPD) patients with exacerbations from pneumonia are given IV steroids without terrible consequences? I feel that steroids are given a bad rap and in short bursts, as used for treating gout—especially with NSAIDs contraindicated—they are a viable option.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

With creatinines of 1.5 to 1.8 in a similar setting, IV colchicine can be tried at 1 mg and possibly repeated in 24 hours. I have used this administrative route many times in the past with good results. The referring attending is always reluctant to use it as well and, unfortunately, formularies are following suit.

Steve Fink, DO, Chief of Rheumatology

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

VA Medical Center, Seminole, Fla.

 

The patient most likely has gout, but he could have a septic knee. I feel you have no choice but to aspirate his knee. I have aspirated and injected hundreds of joints in patients on coumadin. To my knowledge, none has developed a hemarthrosis. Given your patient’s circumstances I would have no problem aspirating his knee. If crystals were seen and the gram stain is negative, I would then treat with intra-articular steroids.

IV colchicines are not on formulary in many hospitals and a bad idea with elevated creatinine. ACTH is not much different than exogenous steroids, but would be my second option.

James S. Cohen, MD, Rheumatologist

Arthritis Care Center, Indianapolis, Ind.

 

I think I’d vote for an intra-articular injection of steroids as long as some antibiotics were already on board, and I’d strongly consider colchicine 0.6 QOD or Q3D to prevent future flares, as the likely trigger of lasix with congestive heart failure is going to continue. Perhaps the risk of an intra-articular bleed with an INR of 3 is less than the likely morbidity of ensuing inflammation in that knee.

Jonathan Samuels, MD, Director, Clinical Immunology Laboratory

NYU Hospital for Joint Diseases, New York City

 

I would have given IV colchicine, 1 mg x1, to your elderly man with gout on top of multisystem failure.

Ronenn Roubenoff, MD, MHS

Senior Director, Immunology Medical Research

Biogen Idec, Inc., Cambridge, Mass.

 

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:GoutQualityTreatment

Related Articles

    Colchicine: An Ancient Drug with Modern Uses

    August 11, 2021

    Discovered more than 3,000 years ago, colchicine is one of the oldest drugs still in use today. Like most old remedies, colchicine is a chemical substance found in many plants, most notably in colchicum autumnale, known as wild saffron or autumn crocus. It was mentioned in the oldest Egyptian medical text, Ebers Papyrus (circa 1550…

    Therapeutic Value of Colchicine in Osteoarthritis, Cardiovascular Disease Explored at the ACR/ARHP Winter Rheumatology Symposium

    April 2, 2014

    Drug’s antiinflammatory properties may help alleviate pain in patients with OA, reduce risk of myocardial infarction, but toxicity, drug interactions need to be considered

    Case Report: Warfarin-Induced Non-Uremic Calciphylaxis Mimicking Vasculitis

    May 13, 2021

    Calciphylaxis, or calcific uremic arteriolopathy, is a rare disease characterized by calcification of the arterioles and capillaries in the dermis and subcutaneous tissue, resulting in thrombus formation and subsequent skin ischemia and necrosis.1 This serious condition most commonly occurs in patients with end-stage renal disease (ESRD) requiring dialysis or in kidney transplant recipients. In rare…

    Basics of Biologic Joint Reconstruction

    April 6, 2012

    For young patients especially, this can delay knee replacement and provide better outcomes.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences